Danish Pharmacovigilance Update, March 2017
18 April 2017
In this issue
- The European Pharmacovigilance Risk Assessment Committee, PRAC, recommends regulatory measures – including suspension of the marketing authorisation for some gadolinium-containing contrast agents
- The DKMA seeks more knowledge about the use of quetiapine in children and adolescents
- Childhood vaccinations and reported suspected adverse reactions in Q4 of 2016
- EU's list of recommendations on safety signals
- Most recent Direct Healthcare Professional Communications (DHPCs)